Takara Bio USA, Inc.
510 Charmany Drive
15 articles with Takara Bio USA, Inc.
Takara Bio Announces the Completion of a New GMP Facility for Manufacturing Gene and Cell Therapy Products
Takara Bio USA, Inc. announced that its parent company, Takara Bio Inc., has completed the construction of a new facility, the Center for Gene and Cell Therapy Processing II in Shiga, Japan.
Namocell, Takara Bio USA and HepaTx collaborate on single cell genomics analysis for cell therapy to treat late-stage liver diseases
Namocell Inc. announced that it has entered into a collaboration with Takara Bio and HepaTx to use Namocell's Single Cell Dispensers to perform single cell isolation on HepaTx's unique hepatocyte-like cells developed from adipose tissue-derived stromal cells, and characterize them by single cell RNA-seq using Takara Bio's SMART-Seq technology.
Takara Bio Announces Launch of Human iPSC-derived Intestinal Epithelial Cells for Drug Discovery Research
The new Cellartis® Intestinal Epithelial Cells (from ChiPSC18) Kit was jointly developed when Takara Bio received a technology transfer from a differentiation induction method to derive these cells from hiPSCs.
Ground-Breaking Single-Cell Transcriptomic Study Using ICELL8® Technology Reveals Homogeneity in Mono- and Multi-Nucleated Adult Cardiomyocytes
Their work, which appeared recently in Basic Research in Cardiology, elucidated transcriptomic signatures of these cardiomyocytes during induced cardiac hypertrophy.
Takara Bio USA, Inc. is proud to announce that researchers at the University of Helsinki, Universidade Católica Portuguesa, CBQF, and Technische Universität Dresden, Institute of Hydrobiology, along with other collaborators have performed the first trans-Europe surveillance study on antibiotic resistance utilizing the SmartChip Real-Time PCR System.
Takara Bio USA, Inc. announced today that its parent company, Takara Bio Inc., submitted a Drug Master File to the Food and Drug Administration for the liquid formulation of RetroNectin GMP grade on March 15, 2019
Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., is proud to announce that researchers from Steven Henikoff's laboratory have developed a novel epigenomic method, CUT&Tag, for high-throughput profiling of chromatin components in single cells on the ICELL8 Single-Cell System.
Takara Bio granted manufacturing license from the Swedish Medical Product Agency for clinical-grade human embryonic stem cell line derivation and banking
Takara Bio announced that the Medical Products Agency granted a manufacturing license for derivation and banking of human embryonic stem (hES) cells to be produced under GMP conditions at the state-of-the-art laboratory located in Göteborg, Sweden, within Takara Bio Europe's facility.
Takara has been awarded a patent covering the Smart-seq2 method by the Japan Patent Office.
This automated system provides a proven platform for unbiased isolation, evaluation, and selection of over a thousand single cells for downstream analyses, including NGS, backed by recent citations in the literature.
Takara Bio USA Release: Company And TeselaGen Biotechnology Release A Powerful New Primer Tool For Easy Design Of In-Fusion Cloning Experiments
Takara Bio USA Announces The Launch Of Human Ipsc-Derived Beta Cells For Drug Screening And Diabetes Research
Takara Bio USA And Integrated DNA Technologies Announce Collaboration To Support Targeted RNA Sequencing